Is the regulatory world ready for "nanosimilars"?
This article was originally published in Scrip
In the beginning there were generics. Then came biosimilars. Now the regulatory world is preparing for the appearance of a new kind of follow-on product: "nanosimilars", or versions of the first generation of nanomedicines, whose patents are on the way to expiry.
You may also be interested in...
A product that was initially turned down for marketing approval in the EU has now been given the green light for use on the National Health Service in Scotland, following a similar recommendation in England late last year.
Coronavirus Notebook: WHO Accelerator Project Languishes, Novel Treatments Are Explored, Gilead Submits US Remdesevir Filing
Gilead files for US approval of remdesivir and boosts investment in manufacturing capacity, more funding is needed for the global ACT Accelerator initiative, and the US and China are rated among the worst responders to the COVID-19 pandemic.
The DIA Europe 2020 conference heard from regulators and health technology assessment bodies about the problems that can arise over poorly defined patient populations and a lack of comparator data when making reimbursement decisions.